SCHEMBL40679

SCHEMBL40679

O=C1CCCC(=O)N1Cc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
ELANE P08246 2/20 0.59
F2 P00734 1/20 0.59
PLG P00747 1/20 0.59
CTSG P08311 1/20 0.59
CMA1 P23946 1/20 0.59
CTRC Q99895 1/20 0.59
L3MBTL1 Q9Y468 2/20 0.58
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
GSK3A P49840 4/20 0.56
GSK3B P49841 4/20 0.56
MGLL Q99685 1/20 0.55
CYP1A2 P05177 1/20 0.55
GAA P10253 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ALDH1A1 P00352 2/20 0.55
APAF1 O14727 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL290791 0.91 POLB (0.70) POLBELANEF2PLGCTSG
Bicarbonate SCHEMBL25171118 0.86 POLB (0.64) POLBELANEF2PLGCTSG
SCHEMBL30905277 0.84 POLB (0.82) POLBL3MBTL1MEN1KMT2ACYP1A2
SCHEMBL11620172 0.82 ELANE (0.57) POLBELANEF2PLGCTSG
SCHEMBL5769842 0.80 MGLL (0.65) POLBELANEF2PLGCTSG
SCHEMBL19233352 0.80 KMT2A (0.69) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL11105334 0.80 MEN1 (0.50) L3MBTL1MEN1KMT2AMGLLCYP1A2
SCHEMBL24083677 0.80 ALDH1A1 (0.58) MEN1KMT2AGAASMN1; SMN2ALDH1A1
SCHEMBL9390734 0.80 KMT2A (0.62) L3MBTL1MEN1KMT2AGSK3AGSK3B
SCHEMBL6819071 0.80 MEN1 (0.46) POLBL3MBTL1MEN1KMT2AGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119661541-A Synthesis method of 6- (tert-butoxycarbonyl) -3, 6-diazabicyclo [3.1.1] heptane 上海馨远医药科技有限公司 2025-03-21 CN claimed
CN-119661541-A Synthesis method of 6- (tert-butoxycarbonyl) -3, 6-diazabicyclo [3.1.1] heptane 上海馨远医药科技有限公司 2025-03-21 CN disclosed
CN-119661541-A Synthesis method of 6- (tert-butoxycarbonyl) -3, 6-diazabicyclo [3.1.1] heptane 上海馨远医药科技有限公司 2025-03-21 CN disclosed
US-20230372915-A1 MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2023-11-23 US disclosed
US-20230372915-A1 MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2023-11-23 US disclosed
US-11731116-B2 Manganese based complexes and uses thereof for homogeneous catalysis YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2023-08-22 US disclosed
US-11731116-B2 Manganese based complexes and uses thereof for homogeneous catalysis YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2023-08-22 US disclosed
EP-3919466-A1 MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS Yeda Research and Development Co. Ltd (IL) 2021-12-08 EP disclosed
EP-2672561-B1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME MITSUBISHI CHEM CORP (JP) 2019-04-17 EP disclosed
WO-2017137984-A1 MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2017-08-17 WO disclosed
US-20070276001-A1 Biphenyl-pyrazolecarboxamide compounds CONCERT PHARMACEUTICALS INC. (US) 2007-11-29 US disclosed
US-20070276001-A1 Biphenyl-pyrazolecarboxamide compounds CONCERT PHARMACEUTICALS INC. (US) 2007-11-29 US disclosed
US-20070276001-A1 Biphenyl-pyrazolecarboxamide compounds CONCERT PHARMACEUTICALS INC. (US) 2007-11-29 US disclosed
WO-2007033366-A2 BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS CONCERT PHARMACEUTICALS INC. (US) 2007-03-22 WO disclosed
WO-2007033366-A2 BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS CONCERT PHARMACEUTICALS INC. (US) 2007-03-22 WO disclosed
US-20070066657-A1 obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist CONCERT PHARMACEUTICALS INC. (US) 2007-03-22 US disclosed
US-20070066657-A1 obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist CONCERT PHARMACEUTICALS INC. (US) 2007-03-22 US disclosed
US-20070066657-A1 obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist CONCERT PHARMACEUTICALS INC. (US) 2007-03-22 US disclosed
US-4038273-A Piperidone intermediates useful in the preparation of aryldecahydropyrrolo [3,4-f]quinolines E. R. SQUIBB & SONS, INC. (US) 1977-07-26 US disclosed
US-3963724-A Intermediates useful in the preparation of aryldecahydropyrrolo[3,4-f]quinolines E. R. SQUIBB & SONS, INC. (US) 1976-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372915-A1 MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS ADH1C, OTC, MLEC POLB 486/4885ELANE 740/4885F2 611/4885
US-20070276001-A1 Biphenyl-pyrazolecarboxamide compounds CNR2, CNR1, GPR119 POLB 3468/4885ELANE 1666/4885F2 1407/4885
US-20070066657-A1 obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist CNR2, CNR1, GPR119 POLB 2594/4885ELANE 2540/4885F2 1090/4885
US-11731116-B2 Manganese based complexes and uses thereof for homogeneous catalysis ADH1C, OTC, ADH5 POLB 484/4885ELANE 716/4885F2 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.